Drug Profile
EXO 226
Latest Information Update: 14 May 2003
Price :
$50
*
At a glance
- Originator Exocell
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetic nephropathies
Most Recent Events
- 14 May 2003 No development reported - Phase-III for Diabetic nephropathies in USA (PO)
- 05 Jan 2001 EXO 226 is available for licensing (http://www.exocell.com)
- 23 Aug 1999 Phase-III clinical trials for Diabetic nephropathies in USA (PO)